Outcomes of Vascular Interventions in Takayasu Arteritis and the Role of Biologic Therapy: A Multicenter Retrospective Study
International Journal of Rheumatic Diseases · 2026-06 · 29 (6)
DOI: 10.1111/1756-185x.70724 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 08.06.2026. Verfasst von Aysegul Avcu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Takayasu Arteritis, Endovascular Procedures, Biological Products, Biological Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objectives
Takayasu arteritis (TAK) may lead to arterial stenosis/occlusion and aneurysms, occasionally requiring vascular interventions. We evaluated outcomes, restenosis, and complications after vascular interventions in TAK and explored factors associated with restenosis.
Methods
We retrospectively included TAK patients who underwent extracardiac endovascular or surgical vascular interventions before or after TAK diagnosis across eight tertiary centers (1995–2024). Indications, disease activity status at the time of intervention, procedural characteristics, early/late outcomes, major complications, and restenosis were recorded. Restenosis was defined as > 70% stenosis on follow‐up imaging performed ≥ 3 months after the procedure. Restenosis analyses were restricted to steno‐occlusive lesions.
Results
We included 119 patients with 201 treated lesions (185 steno‐occlusive lesions; 16 aneurysms/dissections). Of all procedures, 61.2% ( n = 123) were performed after TAK diagnosis under immunosuppressive therapy. Follow‐up imaging was available for 170/185 steno‐occlusive procedures, and restenosis status was evaluable in 168 procedures; restenosis occurred in 82/168 (48.8%) with a median time to restenosis of 19.5 months. In exploratory Kaplan–Meier analysis, 1‐, 3‐, and 5‐year restenosis‐free patency rates were 76.8%, 63.6%, and 56.5%, respectively. In analyses restricted to post‐diagnosis steno‐occlusive procedures, crude restenosis was significantly less frequent under biologic therapy than without biologic therapy (30.8% vs. 53.1%; Fisher's exact p = 0.040); however, biologic therapy was not associated with time to restenosis in Cox regression (HR 1.01, 95% CI 0.51–1.99; p = 0.97) or patient‐clustered Cox analysis (HR 1.01, 95% CI 0.47–2.18; p = 0.98). Major complication rates were 3.9% for endovascular procedures and 12.5% for surgical procedures. Overall mortality was 11.8%, with two deaths attributed to procedure‐related complications.
Conclusions
Vascular interventions in selected patients with Takayasu arteritis were associated with acceptable major complication rates. Among post‐diagnosis steno‐occlusive procedures, biologic therapy was associated with lower restenosis rates in crude analyses; however, this association was not sustained after accounting for restenosis timing. Therefore, the potential role of biologic therapy in improving post‐interventional vascular outcomes should be interpreted cautiously and requires confirmation in prospective studies with standardized imaging surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Türkiye.
- Department of Internal Medicine, Division of Rheumatology, Bahcesehir University, School of Medicine, Istanbul, Türkiye.
- Department of Internal Medicine, Division of Rheumatology, Gazi University, School of Medicine, Ankara, Türkiye.
- Department of Internal Medicine, Division of Rheumatology, Dokuz Eylul University, School of Medicine, Izmir, Türkiye.
- Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
- Department of Internal Medicine, Division of Rheumatology, Ege University, School of Medicine, Izmir, Türkiye.
ORCID-Profile: Aysegul Avcu, Ömer Uludağ, Senar San, Hasan Kocaayan, Ayten Yazici, Kenan Aksu, Haner Direskeneli, Fatma Alibaz-Oner
Zitieren
APA
Avcu, A., Kaymaz-Tahra, S., Kardas, R. C., Basibuyuk, F., Uludağ, Ö., Kerim, D., San, S., Kocaayan, H., Ademoglu, Z., Kenar Artin, G., Ince, B., Emmungil, H., Akar, S., Cefle, A., Yazici, A., Keser, G., Aksu, K., İnanc, M., Onen, F., …, & Alibaz-Oner, F. (2026). Outcomes of Vascular Interventions in Takayasu Arteritis and the Role of Biologic Therapy: A Multicenter Retrospective Study. International Journal of Rheumatic Diseases, 29(6). https://doi.org/10.1111/1756-185x.70724
Vancouver
Avcu A, Kaymaz-Tahra S, Kardas RC, Basibuyuk F, Uludağ Ö, Kerim D, et al. Outcomes of Vascular Interventions in Takayasu Arteritis and the Role of Biologic Therapy: A Multicenter Retrospective Study. International Journal of Rheumatic Diseases. 2026;29(6). doi:10.1111/1756-185x.70724
BibTeX
@article{Avcu2026,
author = {Avcu, Aysegul and Kaymaz-Tahra, Sema and Kardas, Rıza Can and Basibuyuk, Fatma and Uludağ, Ömer and Kerim, Duygu and San, Senar and Kocaayan, Hasan and Ademoglu, Zeliha and Kenar Artin, Gokce and Ince, Burak and Emmungil, Hakan and Akar, Servet and Cefle, Ayse and Yazici, Ayten and Keser, Gokhan and Aksu, Kenan and İnanc, Murat and Onen, Fatos and Kucuk, Hamit and Direskeneli, Haner and Alibaz-Oner, Fatma},
title = {Outcomes of Vascular Interventions in Takayasu Arteritis and the Role of Biologic Therapy: A Multicenter Retrospective Study},
journal = {International Journal of Rheumatic Diseases},
year = {2026},
volume = {29},
number = {6},
doi = {10.1111/1756-185x.70724}
}
EUVIMED